Complete Remission/Chronic Phase 
At least 14 days after discontinuation of G-CSF 
and completion of PBSC collection, patients will 
undergo therapy with 5-FU. 
A pre-FU marrow aspirate and biopsy will be 
obtained to ensure adequate marrow cellularity 
(>30%) and to document continued remission/chronic 
phase. 5-FU administration will not proceed until 
cellularity > 30%. Patients must have achieved a 
complete remission/return to chronic phase with 
one or two cycles of cytoreductive chemotherapy 
before proceeding to 5-FU treatment, marrow 
harvest and transplant. 
Bone marrow harvest will occur on day 10 after the 
first dose of 5-f luorouracil, and no later than 
day -5 prior to transplantation (see below) . 
Marrow harvests will be delayed in patients who 
have not achieved an ANC of >1000/mm 3 or platelet 
count of > 100,000/mm 3 by day 10 post-FU. 
10 . 5-Fluorouracil Priming of Marrow ; 
Patients will receive: 5-FU 15 mg/kg IV bolus QD x 
3 followed by marrow harvest 10 days later. 
Bone marrow aspirate and biopsy will be performed 
on day 5 and on day 15 following the initial dose 
of 5-f luorouracil to assess cellularity, 
progenitor content and retroviral infectivity. 
11. Timing of Stem Cell (Peripheral Blood/Marrow) 
Transplant : 
Patients in 1st chronic phase (Group 1) will 
proceed to stem cell transplant preferably, but 
not exclusively within the first 12 months from 
the time of bone marrow harvest. 
12 . Resuming interferon after harvest in patients who 
do not proceed directly to transplant : 
In patients who have responded to interferon 
maximally and have undergone marrow harvest +/- 
stem cell collection, interferon may be resumed at 
previous dosages until transplant. 
13 . Discontinuation of interferon prior to transplant : 
[158] 
Recombinant DNA Research, Volume 16 
